PDCD1 and melanoma: The clinical trial identified as NCT03241927 is currently investigating the effect of pembrolizumab on NK cell exhaustion in melanoma based on the idea that releasing the PD-1 immune checkpoint in NK cells may help them to infiltrate the tumor and exert their effector functions against the tumor.